This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
View All Zacks #1 Ranked Stocks
Zacks News
LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer Therapy
by Zacks Equity Research
Eli Lilly secures EU approval for Alzheimer's drug Kisunla and gains FDA nod to breast cancer therapy Inluriyo.
BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL
by Zacks Equity Research
FDA issues CRL to Biogen's regulatory filing seeking approval for a higher dose of SMA drug, Spinraza. The company plans prompt resubmission.
IONS' Rare Neurological Disease Drug Meets Late-Stage Study Goal
by Zacks Equity Research
Ionis' zilganersen hits its phase III goal in Alexander disease, paving the way for a potential FDA filing in early 2026.
Biogen Gets EU Nod for First Postpartum Depression Drug
by Zacks Equity Research
BIIB secures EU approval for Zurzuvae, the first oral treatment for postpartum depression, boosting its long-term growth prospects.
Will AbbVie's Neuroscience Portfolio Continue to Aid Top-line Growth?
by Sundeep Ganoria
ABBV's expanding neuroscience portfolio, led by Botox, Vraylar and new launches like Vyalev, continues to fuel top-line growth.
IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride
by Zacks Equity Research
Ionis surges to a 52-week high after Tryngolza shows strong triglyceride reductions and cuts acute pancreatitis risk by 85% in late-stage studies.
Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales
by Kinjel Shah
Eli Lilly's growing lineup beyond Mounjaro and Zepbound, including Omvoh and Jaypirca, is set to fuel revenue growth through 2025.
Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of Leqembi
by Zacks Equity Research
BIIB wins FDA approval for Leqembi Iqlik, a fast, subcutaneous option for early Alzheimer's patients transitioning from IV infusions.
DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26
by Zacks Equity Research
Denali Therapeutics posts narrower-than-expected Q2 loss. The company advances multiple rare disease therapies toward potential approvals.
Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
by Zacks Equity Research
BIIB posts Q2 earnings and sales beat, lifts 2025 outlook on new drug growth and displays resilient MS performance.